24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Novartis
Related studies linked through entity extraction aliases.
Overcoming Racial Disparities in Screening Mammography
- Status
- NOT_YET_RECRUITING
- Phase
- NA
24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAs
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
ASCiminib, With or Without Dasatinib Combination, as a 2nd-Line Therapy to ADVANCE the Treatment for Chronic Myelogenous Leukemia in Chronic Phase (ASC2ADVANCE)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Optimizing Referral Pathways for Patients With Hematuria and Moderate-Severe Proteinuria
- Status
- NOT_YET_RECRUITING
- Phase
- NA
Multiple Sclerosis Implementation Network (Registry)
- Status
- RECRUITING
- Phase
- N/A
Electronic Letters to Improve Patient Activation in IHD: The NUDGE-IHD Trial
- Status
- NOT_YET_RECRUITING
- Phase
- NA
This Clinical Trial is a Retrospective, Multicenter Cohort Study Evaluating the Real-world Characteristics and Risk of Disease Recurrence in Hormone Receptor-positive, HER2-negative Early Breast Cancer.
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL
- Status
- RECRUITING
- Phase
- PHASE1
Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib
- Status
- RECRUITING
- Phase
- PHASE3
Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Asciminib in HER2+ Breast Cancer Brain Metastases
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617
- Status
- RECRUITING
- Phase
- PHASE1
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
- Status
- WITHDRAWN
- Phase
- PHASE2
177LuPSMA in Renal Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy
- Status
- RECRUITING
- Phase
- PHASE2